Federal Register of Legislation - Australian Government

Primary content

PB 48 of 2012 Arrangements as made
This instrument amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (No. PB 79 of 2011) to make changes to the special arrangement relating to the efficient funding of chemotherapy.
Administered by: Health
Made 24 Jul 2012
Registered 27 Jul 2012
Tabled HR 14 Aug 2012
Tabled Senate 14 Aug 2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 48 of 2012

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 6)

 

National Health Act 1953

___________________________________________________________________________

 

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.

Dated  24 July 2012

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 6).

 

(2)                This Instrument may also be cited as PB 48 of 2012.

 

2             Commencement

                This Instrument commences on 1 August 2012.

3              Amendments to PB 79 of 2011

                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).

 

 


Schedule 1                   Amendments

 

 

[1]    Section 3, after definition for infusion prescription

insert:

National Health Reform Agreement has the meaning given in the Federal Financial Relations Act 2009.

[2]    Section 3, definition of participating hospital authority

substitute:

participating hospital authority means an approved hospital authority for a public hospital that is participating in a Pharmaceutical Reform Arrangement within the meaning of the National Health Reform Agreement.

[3]    Schedule 1 Part 1, after entry for Bortezomib

insert in the columns in the order indicated:

 

        Cabazitaxel

Concentrated injection 60mg (as acetone solvate) in 1.5 mL, with diluent

Injection

Jevtana

SW

MP

C7000

C7001

D

 

[4]    Schedule 1 Part 1, entry for Docetaxel in the form Injection set containing 1 single use vial concentrate for I.V. infusion 20 mg (anhydrous) in 0.5 mL with solvent, in the column headed ‘Circumstances’

omit:

C3884

 insert after C3956:

C7002

[5]    Schedule 1 Part 1, entry for Docetaxel in the form Injection set containing 1 single use vial concentrate for I.V. infusion 80 mg (anhydrous) in 2 mL with solvent, in the column headed ‘Circumstances’

omit:

C3884

 insert after C3956:

C7002

[6]    Schedule 1 Part 1, entry for Docetaxel in the form Powder for I.V. infusion 20 mg with solvent, in the column headed ‘Circumstances’

omit:

C3884

 insert after C3955:

C7002

[7]    Schedule 1 Part 1, entry for Docetaxel in the form Powder for I.V. infusion 80 mg with solvent, in the column headed ‘Circumstances’

omit:

C3884

insert after C3955:

C7002

[8]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 140 mg in 7 mL, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[9]    Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 160 mg in 16 mL, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[10]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 1 mL with manner of administration Injection and brand Oncotaxel 20, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[11]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 1 mL with manner of administration Injection and brand Taxotere, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[12]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[13]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand Docetaxel Ebewe, in the column headed ‘Circumstances’

omit:

C3884

insert after C3955:

C7002

[14]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 20 mg in 2 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[15]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 4 mL with manner of administration Injection and brand Oncotaxel 80, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[16]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 4 mL with manner of administration Injection and brand Taxotere, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[17]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand DBL Docetaxel Concentrated Injection, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[18]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand Docetaxel Ebewe, in the column headed ‘Circumstances’

omit:

C3884

insert after C3955:

C7002

[19]  Schedule 1 Part 1, entry for Docetaxel in the form Solution concentrate for I.V. infusion 80 mg in 8 mL with manner of administration Injection and brand Docetaxel Sandoz, in the column headed ‘Circumstances’

omit:

C3884

insert after C3956:

C7002

[20]  Schedule 1 Part 1, after entry for Topotecan in the form Powder for I.V. infusion 4 mg (as hydrochloride) with manner of administration Injection and brand Hycamtin

insert in the columns in the order indicated:

 

 

 

Topotecan Kabi

PK

MP

C3186

D

 

 

 

 

 

 

 

 

 

[21]  Schedule 1 Part 2, after entry for Bortezomib

insert in the columns in the order indicated:

 

        Cabazitaxel

 

55

5

 

 

 

 

 

 

 

 

 

 

 

 

 

 

[22]  Schedule 4, after entry for Bortezomib

insert in the columns in the order indicated:

 

Cabazitaxel

C7000

 

Where the patient is receiving treatment in the community setting or at/from a Private Hospital, treatment, in combination with prednisone or prednisolone, of castration resistant metastatic carcinoma of the prostate in a patient who has failed treatment with docetaxel due to resistance or intolerance and has a WHO performance status of 2 or less.

Compliance with Authority Required procedures

 

C7001

 

Where the patient is receiving treatment at/from a Public Hospital, treatment, in combination with prednisone or prednisolone, of castration resistant metastatic carcinoma of the prostate in a patient who has failed treatment with docetaxel due to resistance or intolerance and has a WHO performance status of 2 or less.

Compliance with Authority Required procedures - Streamlined Authority Code 7001

 

[23]  Schedule 4, entry for Docetaxel

omit:

 

C3884

P3884

Treatment of androgen independent (hormone refractory) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%, where docetaxel is used as first-line chemotherapy and administered in three weekly cycles

Compliance with Authority Required procedures – Streamlined Authority Code 3884

insert after C3956:

 

C7002

P7002

Treatment of androgen independent (castration resistant) metastatic carcinoma of the prostate in a patient with a Karnofsky performance-status score of at least 60%, where docetaxel is used as first-line chemotherapy and administered in three weekly cycles

Compliance with Authority Required procedures – Streamlined Authority Code 7002

 

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.